Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniel L. Stoler is active.

Publication


Featured researches published by Daniel L. Stoler.


Cancer Epidemiology, Biomarkers & Prevention | 2009

Chronic Periodontitis and the Incidence of Head and Neck Squamous Cell Carcinoma

Mine Tezal; Maureen Sullivan; Andrew Hyland; James R. Marshall; Daniel L. Stoler; Mary E. Reid; Thom R. Loree; Nestor R. Rigual; Mihai Merzianu; Linda Hauck; Cheryl Lillis; Jean Wactawski-Wende; Frank A. Scannapieco

Substantial evidence supports an association between chronic infections/inflammation, and cancer. The aim of this study was to assess the effect of chronic periodontitis on head and neck squamous cell carcinoma (HNSCC). The study population consisted of new patients at the Department of Dentistry and Maxillofacial Prosthetics, Roswell Park Cancer Institute between 1999 and 2005. Cases were patients diagnosed with primary HNSCC. Controls were all patients seen during the same time period but negative for malignancy. Patients age <21 years, edentulous, immunocompromised, and those with history of cancer were excluded. Periodontitis was measured by alveolar bone loss (ABL) from panoramic radiographs by one examiner blind to cancer status. A total of 473 patients (266 cases and 207 controls) were included in the study. Each millimeter of ABL was associated with >4-fold increased risk of HNSCC (odds ratio, 4.36; 95% confidence interval, 3.16-6.01) after adjustment for age, gender, race/ethnicity, marital status, smoking status, alcohol use, and missing teeth. The strength of the association was greatest in the oral cavity, followed by oropharynx and larynx. The association persisted in subjects who never used tobacco and alcohol. There was a significant interaction between smoking and ABL (P = 0.03). Patients with periodontitis were more likely to have poorly differentiated oral cavity SCC than those without periodontitis (32.8% versus 11.5%; P = 0.038). This study suggests that chronic periodontitis is an independent risk factor for HNSCC and smoking modifies this association. These results have implications for practical and safe strategies for prevention, diagnosis, and treatment of HNSCC. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2406–12)


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2003

Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy.

Sam M. Wiseman; Thom R. Loree; Nestor R. Rigual; Wesley L. Hicks; Wade G. Douglas; Garth R. Anderson; Daniel L. Stoler

Anaplastic thyroid cancer ranks among the most lethal of all human malignancies. Its rarity and rapidly fatal course have made it a difficult cancer to both study and treat. Unfortunately, there has been little progress in the management and control of this malignancy. Anaplastic transformation, or the intratumoral evolution of anaplastic carcinoma from pre‐existing differentiated thyroid cancer, has become a well‐accepted process, despite a limited understanding of its underlying mechanisms.


Genes, Chromosomes and Cancer | 1997

Genomic instability in sporadic colorectal cancer quantitated by inter-simple sequence repeat PCR analysis

Mark Basik; Daniel L. Stoler; Konstantinos Kontzoglou; Miguel A. Rodriguez-Bigas; Nicholas J. Petrelli; Garth R. Anderson

Genomic instability plays a major role in cancer by facilitating tumor progression and tumor heterogeneity. Inter‐simple sequence repeat (inter‐SSR) PCR has been developed to provide a rapid and reproducible technique for quantitation of the major type of genomic instability observed in sporadic tumors, namely, that manifesting itself as amplifications, deletions, translocations, and insertions. Evaluation of 59 sporadic colorectal cancers by inter‐SSR PCR has demonstrated a wide range of instability, independent of tumor stage at diagnosis. Comparison of these data and the results of microsatellite PCR analysis reveals an association of high genomic instability with loss of heterozygosity but no association with the replication error phenomenon arising from defects in mismatch repair. Genes Chromosom. Cancer 18:19–29, 1997.


Archives of Otolaryngology-head & Neck Surgery | 2009

Chronic periodontitis-human papillomavirus synergy in base of tongue cancers.

Mine Tezal; Maureen A. Sullivan Nasca; Daniel L. Stoler; Thomas Melendy; Andrew Hyland; Philip J. Smaldino; Nestor R. Rigual; Thom R. Loree

OBJECTIVE To assess whether chronic periodontitis history predicts human papillomavirus (HPV) status in patients with base of tongue cancers. DESIGN Case-control study using existing patient data. SETTING Roswell Park Cancer Institute. PATIENTS Thirty patients newly diagnosed with base of tongue squamous cell carcinoma between 1999 and 2005 for whom both tumor samples and periodontal records were available. Patients younger than 21 years, edentulous, immunocompromised, and those with a history of cancer were excluded. Periodontitis history was assessed on the basis of alveolar bone loss (in millimeters) from panoramic radiographs by one examiner who was blinded to cancer status. MAIN OUTCOME MEASURE HPV-16 and HPV-18 DNA were identified on paraffin-embedded tumor samples by polymerase chain reaction. Multiple logistic regression was used to estimate odds ratios and 95% confidence intervals. RESULTS The prevalence of tumors positive for HPV-16 DNA was 21 of 30 (70%). None of the samples were positive for HPV-18 DNA. Compared with participants with HPV-negative tumors, patients with HPV-positive tumors had significantly higher mean alveolar bone loss (3.90 mm vs 2.85 mm, P = .01). After adjustment for age at diagnosis, sex, race/ethnicity, alcohol use, smoking status, and number of missing teeth, every millimeter of alveolar bone loss was associated with an approximately 4-fold (odds ratio, 3.96; 95% confidence interval, 1.18-13.36) increased risk of HPV-positive tumor status. Number of missing teeth was not associated with tumor HPV status (odds ratio, 0.95; 95% confidence interval, 0.74-1.21). CONCLUSIONS Chronic periodontitis may be a significant factor in the natural history of HPV infection in patients with base of tongue cancers. Additional confirmation in larger studies is required.


Annals of Surgical Oncology | 2003

Squamous Cell Carcinoma of the Head and Neck in Nonsmokers and Nondrinkers: An Analysis of Clinicopathologic Characteristics and Treatment Outcomes

Sam M. Wiseman; Helen Swede; Daniel L. Stoler; Garth R. Anderson; Nestor R. Rigual; Wesley L. Hicks; Wade G. Douglas; Dongfeng Tan; Thom R. Loree

Background: The objective of this study was to describe the clinicopathologic manifestations of disease and outcomes of treatment among individuals without a history of smoking tobacco or consuming alcohol who develop head and neck cancer.Methods: Of 1648 invasive head and neck cancer cases treated between 1970 and 2001 at Roswell Park Cancer Institute, 40 patients were identified as never having smoked tobacco or consumed alcohol during their lifetime. These cases were reviewed to gather data on multiple clinicopathologic variables.Results: Mean age at presentation of nonsmoker/nondrinker head and neck cancer patients was 60 years (range, 27 to 90 years), and 78% (n = 31) of the patients were women. The distributions of tumor sites were 75.0% oral cavity (n = 30), 20.0% oropharynx (n = 8), and 5.0% larynx (n = 2). Sixteen patients (40%) experienced a recurrence of disease during the follow-up period, and 10 patients (25.0%) developed a second primary tumor a median of 6 years after their initial diagnosis.Conclusions: The nonsmoker/nondrinker head and neck cancer patient tends to be elderly and female, have oral cavity primary tumors, and be predisposed to second primary tumor development.


Genetics in Medicine | 2007

Challenges in array comparative genomic hybridization for the analysis of cancer samples

Norma J. Nowak; Jeffrey C. Miecznikowski; Stephen Moore; Daniel Gaile; Dolores Bobadilla; David D. Smith; Kemp H. Kernstine; Stephen J. Forman; Paulette Mhawech-Fauceglia; Mary E. Reid; Daniel L. Stoler; Thom R. Loree; Nestor R. Rigual; Maureen Sullivan; Lawrence M. Weiss; David G. Hicks; Marilyn L. Slovak

Purpose: To address some of the challenges facing the incorporation of array comparative genomic hybridization technology as a clinical tool, including archived tumor tissue, tumor heterogeneity, DNA quality and quantity, and array comparative genomic hybridization platform selection and performance.Methods: Experiments were designed to assess the impact of DNA source (e.g., archival material), quantity, and amplification on array comparative genomic hybridization results. Two microdissection methods were used to isolate tumor cells to minimize heterogeneity. These data and other data sets were used in a further performance comparison of two commonly used array comparative genomic hybridization platforms: bacterial artificial chromosome (Roswell Park Cancer Institute) and oligonucleotide (Agilent Technologies, Santa Clara, CA).Results: Array comparative genomic hybridization data from as few as 100 formalin-fixed, paraffin-embedded cells isolated by laser capture microdissection and amplified were remarkably similar to array comparative genomic hybridization copy number alterations detected in the bulk (unamplified) population. Manual microdissection from frozen sections provided a rapid and inexpensive means to isolate tumor from adjacent DNA for amplification and array comparative genomic hybridization. Whole genome amplification introduced no appreciable allele bias on array comparative genomic hybridization. The array comparative genomic hybridization results provided by the bacterial artificial chromosome and Agilent platforms were concordant in general, but bacterial artificial chromosome array comparative genomic hybridization showed far fewer outliers and overall less technical noise, which could adversely affect the statistical interpretation of the data.Conclusions: This study demonstrates that copy number alterations can be robustly and reproducibly detected by array comparative genomic hybridization in DNA isolated from challenging tumor types and sources, including archival materials, low DNA yield, and heterogeneous tissues. Furthermore, bacterial artificial chromosome array comparative genomic hybridization offers the advantage over the Agilent oligonucleotide platform of presenting fewer outliers, which could affect data interpretation.


Archives of Otolaryngology-head & Neck Surgery | 2012

Local inflammation and human papillomavirus status of head and neck cancers.

Mine Tezal; Frank A. Scannapieco; Jean Wactawski-Wende; Andrew Hyland; James R. Marshall; Nestor R. Rigual; Daniel L. Stoler

OBJECTIVE To determine whether periodontitis is associated with human papillomavirus (HPV) status of head and neck squamous cell carcinoma (HNSCC). DESIGN AND SETTING Hospital-based case-control study in a comprehensive cancer center. PATIENTS Evaluation included all patients diagnosed with incident primary squamous cell carcinoma of the oral cavity, oropharynx, and larynx between 1999 and 2007 for whom tissue samples and dental records were available (N = 124). Patients younger than 21 years and those with a history of cancer were excluded. Periodontitis history was assessed by alveolar bone loss in millimeters from panoramic radiographs by one examiner blinded to cancer status. MAIN OUTCOME MEASURE The presence of HPV-16 DNA in paraffin-embedded tumor samples was identified by polymerase chain reaction. RESULTS The prevalence of HPV-positive HNSCC was 50 of 124 patients (40.3%). A higher proportion of oropharyngeal cancers were HPV-positive (32 of 49 [65.3%]) compared with oral cavity (9 of 31 [29.0%]) and laryngeal (9 of 44 [20.5%]) cancers. Each millimeter of alveolar bone loss was associated with 2.6 times increased odds (odds ratio [OR], 2.61; 95% CI, 1.58-4.30) of HPV-positive tumor status after adjustment for age at diagnosis, sex, and smoking status. The strength of the association was greater among patients with oropharyngeal SCC (OR, 11.70; 95% CI, 2.09-65.53) compared with those with oral cavity SCC (OR, 2.32; 95% CI, 0.65-8.27) and laryngeal SCC (OR, 3.89; 95% CI, 0.95-15.99). CONCLUSIONS A history of chronic inflammatory disease in the oral cavity may be associated with tumor HPV status in patients with HNSCC. This association seems to be stronger among patients with oropharyngeal cancer compared with those who have oral cavity or laryngeal SCC.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2002

Genomic instability measurement in the diagnosis of thyroid neoplasms

Daniel L. Stoler; Rajiv V. Datta; Melita A. Charles; AnneMarie W. Block; Bruce M. Brenner; Elizabeth Sieczka; Wesley L. Hicks; Thom R. Loree; Garth R. Anderson

Clinically palpable thyroid nodules are present in approximately 10% of the population, although only 5% to 7% of these nodules harbor malignancy. Fine‐needle aspiration has become one of the central tools in the diagnostic armamentarium of the surgeon/endocrinologist. There is, however, up to a 30% indeterminate diagnostic rate associated with this technique, resulting in unnecessary surgical interventions for patients harboring benign disease. A second issue of clinical importance is the unreliability of predicting outcomes based either on histologic findings alone or in combination with clinical staging. To address these diagnostic and clinical shortcomings, we have used measurement of genomic instability as a diagnostic and prognostic indicator for thyroid neoplasms.


Cytogenetic and Genome Research | 1999

Genome-wide allelotyping indicates increased loss of heterozygosity on 9p and 14q in early age of onset colorectal cancer

T. K. Weber; Jeffrey Conroy; B. Keitz; Miguel A. Rodriguez-Bigas; Nicholas J. Petrelli; Daniel L. Stoler; Garth R. Anderson; Thomas B. Shows; Norma J. Nowak

Colorectal cancer remains a significant public health challenge, despite our increased understanding of the genetic mechanisms involved in the initiation and progression of this disorder. It has become clear that multiple mechanisms lead to the tumorigenic phenotype, with familial predisposition syndromes accounting for less than 15% of all colorectal cancers. A genome-wide scan for loss of heterozygosity (LOH) was carried out with 150 highly polymorphic markers in an effort to identify additional loci involved in colorectal tumorigenesis in DNA samples from 42 colorectal cancer patients. The results confirm earlier observations that tumor DNAs from patients with hereditary nonpolyposis colon cancer (HNPCC) either maintain heterozygosity or exhibit altered or additional alleles. DNAs from patients with early onset colorectal carcinomas (diagnosed prior to age 50) revealed a higher overall degree of LOH than DNAs from patients with sporadic colorectal cancers diagnosed later in life (after age 50). While regions on 1p, 10q and 14q are suggestive, statistical analysis of LOH at these regions failed to reach significance. However, LOH at 9p did reveal a statistically significant increase in the early onset patient group, compared to the greater than age 50 group. LOH on 9p may involve inactivation of p16/CDKN2 through aberrant DNA methylation on the remaining chromosome, resulting in a situation analogous to a homozygous deletion of p16 and providing a selective growth advantage to these cells. This marker may prove to be a useful prognostic indicator for patient stratification in the design of therapy for early onset colorectal cancer patients.


Journal of Cellular Physiology | 2010

Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway†

Ricardo Perez; Chad D. Knights; Geetaram Sahu; Jason Catania; Vamsi K. Kolukula; Daniel L. Stoler; Adolf Graessmann; Vasily Ogryzko; Michael J. Pishvaian; Christopher Albanese; Maria Laura Avantaggiati

Tumor‐derived mutant forms of p53 compromise its DNA binding, transcriptional, and growth regulatory activity in a manner that is dependent upon the cell‐type and the type of mutation. Given the high frequency of p53 mutations in human tumors, reactivation of the p53 pathway has been widely proposed as beneficial for cancer therapy. In support of this possibility p53 mutants possess a certain degree of conformational flexibility that allows for re‐induction of function by a number of structurally different artificial compounds or by short peptides. This raises the question of whether physiological pathways for p53 mutant reactivation also exist and can be exploited therapeutically. The activity of wild‐type p53 is modulated by various acetyl‐transferases and deacetylases, but whether acetylation influences signaling by p53 mutant is still unknown. Here, we show that the PCAF acetyl‐transferase is down‐regulated in tumors harboring p53 mutants, where its re‐expression leads to p53 acetylation and to cell death. Furthermore, acetylation restores the DNA‐binding ability of p53 mutants in vitro and expression of PCAF, or treatment with deacetylase inhibitors, promotes their binding to p53‐regulated promoters and transcriptional activity in vivo. These data suggest that PCAF‐mediated acetylation rescues activity of at least a set of p53 mutations. Therefore, we propose that dis‐regulation of PCAF activity is a pre‐requisite for p53 mutant loss of function and for the oncogenic potential acquired by neoplastic cells expressing these proteins. Our findings offer a new rationale for therapeutic targeting of PCAF activity in tumors harboring oncogenic versions of p53. J. Cell. Physiol. 225: 394–405, 2010.

Collaboration


Dive into the Daniel L. Stoler's collaboration.

Top Co-Authors

Avatar

Garth R. Anderson

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Nicholas J. Petrelli

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Nestor R. Rigual

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Miguel A. Rodriguez-Bigas

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Thom R. Loree

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Helen Swede

University of Connecticut Health Center

View shared research outputs
Top Co-Authors

Avatar

Sam M. Wiseman

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Norma J. Nowak

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Jeremy D. Bartos

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Wesley L. Hicks

Roswell Park Cancer Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge